Peanut Allergy-Pipeline Review, H1 2017

Peanut Allergy-Pipeline Review, H1 2017


  • Products Id :- GMDHC9246IDB
  • |
  • Pages: 84
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Peanut Allergy-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peanut Allergy-Pipeline Review, H1 2017, provides an overview of the Peanut Allergy (Immunology) pipeline landscape.

Peanut allergy is common, especially in children. An allergic response to peanuts usually occurs within minutes after exposure, and symptoms range from mild to severe. Peanut allergy signs and symptoms can include skin reactions, such as hives, redness or swelling, itching or tingling in or around the mouth and throat, digestive problems, such as diarrhea, stomach cramps, nausea or vomiting, tightening of the throat, shortness of breath or wheezing and runny nose.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peanut Allergy-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Peanut Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peanut Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Peanut Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 4, 8 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Discovery stages comprises 1, 1 and 1 molecules, respectively.

Peanut Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Peanut Allergy (Immunology).

The pipeline guide reviews pipeline therapeutics for Peanut Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Peanut Allergy (Immunology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Peanut Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Peanut Allergy (Immunology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Peanut Allergy (Immunology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Peanut Allergy (Immunology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Peanut Allergy-Overview

Peanut Allergy-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Peanut Allergy-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Peanut Allergy-Companies Involved in Therapeutics Development

Adverum Biotechnologies Inc

Aimmune Therapeutics Inc

Alfacyte Ltd

Allergy Therapeutics Plc

AnaptysBio Inc

ASIT Biotech SA

Astellas Pharma Inc

BioLingus AG

DBV Technologies SA

HAL Allergy BV

Intrommune Therapeutics

Sanofi

Peanut Allergy-Drug Profiles

aldesleukin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for Peanut Allergy-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for Peanut Allergy-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for Peanut Allergy-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for Peanut Allergy-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ANB-020-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ANN-004-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AR-101-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASP-0892-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DBV-712-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs to Inhibit CYP11A1 for Peanut Allergy and Asthma-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HALMPE-1-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INT-301-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PER-1080-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pnut-ASIT-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Polyvac Peanut-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAR-439794-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SCV-204-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SCV-209-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine 2 for Peanut Allergy-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Peanut Allergy-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Peanut Allergy-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VTC-064-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peanut Allergy-Dormant Projects

Peanut Allergy-Discontinued Products

Peanut Allergy-Product Development Milestones

Featured News & Press Releases

Mar 10, 2017: DBV Technologies Announces Completion of Enrollment of the REALISE Study in Peanut Allergic Children

Mar 06, 2017: Aimmune Therapeutics Presents Clinical Data on Phase 3 Screening and Phase 2 Adherence for AR101 for Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting

Mar 05, 2017: Data at AAAAI 2017 Show Lasting Response and Favorable Safety Profile of Investigational Agent, Viaskin Peanut, Throughout Three Years of Treatment of Peanut Allergic Children

Mar 04, 2017: AnaptysBio Announces Data from Scientific Collaboration with the Benaroya Research Institute Presented at the AAAAI 2017 Annual Meeting

Feb 27, 2017: Aimmune Therapeutics to Present AR101 Clinical Data in Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting

Feb 16, 2017: Aimmune Therapeutics Provides Update on Ongoing AR101 Phase 3 Program for Peanut Allergy Based on FDA Feedback

Feb 06, 2017: Selecta Biosciences Presents Preclinical Data Regarding SVP-Enabled Peanut Allergy Therapeutic Vaccine

Feb 01, 2017: Allergy Therapeutics Announces Positive Efficacy and Safety Data Shown in Peanut Allergy Vaccine

Dec 20, 2016: Astellas Announces FDA Fast Track Designation for ASP0892, DNA Vaccine for Mitigation of Severe Hypersensitivity Reactions due to Peanut Allergy

Dec 13, 2016: AnaptysBio Announces Clearance of U.S. IND and U.K. CTA for ANB020

Nov 28, 2016: Aimmune Therapeutics Completes Global Enrollment of Phase 3 PALISADE Trial of AR101 for the Treatment of Peanut Allergy

Nov 11, 2016: DBV Technologies Announces Poster Presentations at the 2016 American College of Allergy, Asthma, and Immunology Meeting

Oct 26, 2016: DBV Technologies Announces Publication of Positive Viaskin Peanut Data From NIAID-Sponsored Phase II Academic Study in the Journal of Allergy and Clinical Immunology

Oct 24, 2016: Topline Results from Two-Year Follow-Up Study of Viaskin Peanut Show Long-Lasting and High Levels of Desensitization to Peanut

Oct 03, 2016: AnaptysBio Reports ANB020 Top-Line Phase 1 Clinical Trial Results

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Peanut Allergy, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Peanut Allergy, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Peanut Allergy-Pipeline by Adverum Biotechnologies Inc, H1 2017

Peanut Allergy-Pipeline by Aimmune Therapeutics Inc, H1 2017

Peanut Allergy-Pipeline by Alfacyte Ltd, H1 2017

Peanut Allergy-Pipeline by Allergy Therapeutics Plc, H1 2017

Peanut Allergy-Pipeline by AnaptysBio Inc, H1 2017

Peanut Allergy-Pipeline by ASIT Biotech SA, H1 2017

Peanut Allergy-Pipeline by Astellas Pharma Inc, H1 2017

Peanut Allergy-Pipeline by BioLingus AG, H1 2017

Peanut Allergy-Pipeline by DBV Technologies SA, H1 2017

Peanut Allergy-Pipeline by HAL Allergy BV, H1 2017

Peanut Allergy-Pipeline by Intrommune Therapeutics, H1 2017

Peanut Allergy-Pipeline by Sanofi, H1 2017

Peanut Allergy-Dormant Projects, H1 2017

Peanut Allergy-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Adverum Biotechnologies Inc, Aimmune Therapeutics Inc, Alfacyte Ltd, Allergy Therapeutics Plc, AnaptysBio Inc, ASIT Biotech SA, Astellas Pharma Inc, BioLingus AG, DBV Technologies SA, HAL Allergy BV, Intrommune Therapeutics, Sanofi

select a license

Single User License
USD 2000 INR 130400
Site License
USD 4000 INR 260800
Corporate User License
USD 6000 INR 391200

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com